Pharmaceutical

A Growing Number of Biopharmas Leverage Veeva Compass Patient to Improve Commercialization

Modern commercial data helps organizations find new patients and HCPs PLEASANTON, Calif., Dec. 12, 2024 /PRNewswire/ -- Veeva Systems (NYSE:…

1 week ago

AGC Biologics to Manufacture LVV for CAR-T Therapy Approved by FDA for Autolus Therapeutics’ AUCATZYL(R)

CDMO's Cell and Gene Center of Excellence Achieves fifth commercial viral vector product approval, and second overall from FDA in…

1 week ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Journal is the official publication of the International Union of Immunological SocietiesMarlborough, Massachusetts--(Newsfile Corp. - December 12, 2024) - Phio…

1 week ago

Rancho BioSciences, LLC Awarded Great Place to Work(R) Certification for the Third Consecutive Year

Celebrating a Culture of Collaboration and a Mission to Save Lives Through Data SAN DIEGO, CALIFORNIA / ACCESSWIRE / December…

1 week ago

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Transaction follows a $5 million non-dilutive credit line from the same trusted partner, further reinforcing Telomir's financial strength and growth…

1 week ago

180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules

PALO ALTO, CA / ACCESSWIRE / December 12, 2024 / 180 Life Sciences Corp. ("180" or the "Company") is pleased…

1 week ago

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a…

1 week ago

iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress

- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS…

1 week ago

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma

AUSTIN, Texas and GREENWICH, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO) (“Lumos Pharma” or the “Company”),…

1 week ago